Brainsway Ltd (BRSYF)
OTHER OTC:BRSYF
BRSYF Stock Chart & Stats
$11.54
$0.00(0.00%)
At close: 4:00 PM EST
$11.54
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3.26 - $11.87
Previous CloseN/A
Volume2.42K
Average Volume (3M)0.00
Market Cap
$546.14M
Enterprise Value$483.56M
Total Cash (Recent Filing)$67.97M
Total Debt (Recent Filing)$6.82M
Price to Earnings (P/E)45.3
Beta0.13
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding40,033,028
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.11
Price to Sales (P/S)6.62
P/FCF Ratio21.25
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue8.55
Enterprise Value/Gross Profit11.34
Enterprise Value/Ebitda76.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Installed Base GrowthA growing installed base (1,600+ systems; 90 units shipped in quarter, +43% YoY) creates durable revenue visibility via recurring consumables, service and maintenance. Larger installed base supports utilization gains, provider adoption and operating leverage over the medium term.
Improved Cash GenerationSharp improvement to sustained positive operating and free cash flow provides internal funding for growth initiatives, reduces dependence on external financing, and supports reinvestment in sales, R&D and partnerships—enhancing capital efficiency and resilience over coming quarters.
Conservative Balance SheetModest debt and rising equity position a company to fund strategic investments or acquisitions without undue refinancing stress. The conservative balance sheet increases financial flexibility to support commercialization, minority investments and slower repair cycles if needed.
Bears Say
Recent Profit Inflection RiskTransitioning from multi-year losses to profitability is encouraging but creates execution risk: sustaining margin gains and net income requires continued revenue growth, consistent utilization and cost discipline. A reversal would quickly pressure cash generation and investor confidence.
Rising Operating ExpensesElevated S&M and R&D spending supports market expansion and product development but raises fixed cost base. If system placements or utilization growth slow, higher operating expenses could compress operating margins and reduce the cushion from recent cash-flow improvements.
Regulatory & Reimbursement ExposureDelays in partner FDA clearances and dependence on reimbursement policies are structural risks: slower regulatory timelines or adverse reimbursement decisions can delay adoption, reduce clinic utilization and defer recurring service/consumable revenue, impacting multi-quarter growth visibility.
Brainsway News
BRSYF FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $3.26 and its highest was $11.87 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $546.14M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is May 13, 2026 which is in 46 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Mar 11, 2026. The company reported $0.084 earnings per share for the quarter, beating the consensus estimate of N/A by $0.084.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Overvalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,033,028 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.084 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BRSYF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brainsway Ltd
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BRSYF Company Deck
BRSYF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in revenue and system shipments, successful strategic investments, and improved financial guidance. However, there were increased operating expenses and delays in FDA clearance for a strategic partner's product. Overall, the positives significantly outweigh the negatives.View all BRSYF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.24% Mutual Funds
0.23% Other Institutional Investors
99.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---